Diagnosis and management of aspergillosis in the Netherlands: a national survey
Loading...
Date
Authors
Lestrade, P.P.A. Bram
Meis, J.F.G.M. Jacques
Arends, J.P.
Beek, M.T. van der
Brauwer, E. de
Dijk, K van
Greeff, S.C. de
Haas, P.J.
Hodiamont, C.J.
Kuijper, E.J.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.